PMID- 37454513
OWN - NLM
STAT- MEDLINE
DCOM- 20230920
LR  - 20230920
IS  - 1873-3573 (Electronic)
IS  - 0039-9140 (Linking)
VI  - 266
IP  - Pt 1
DP  - 2024 Jan 1
TI  - Spectroscopic determination of hydrophobic adulterant tadalafil by aptasensor 
      based ellipsometry.
PG  - 124940
LID - S0039-9140(23)00691-4 [pii]
LID - 10.1016/j.talanta.2023.124940 [doi]
AB  - Tadalafil is one of the selective phosphodiesterase type 5 inhibitors (PDE5) and 
      serves as the active compound in drugs used for the treatment of erectile 
      dysfunction. These PDE5 inhibitors are prescribed under medical supervision. 
      However, cases of adulteration of dietary supplements with PDE5 inhibitors or 
      their unapproved analogs have been reported worldwide. The presence of the PDE5 
      inhibitors in such supplements poses a serious health risk to consumers, 
      particularly when combined with certain nitrate-containing drugs, as their toxic 
      effects have not been thoroughly assessed and may result in unpredictable adverse 
      reactions. Therefore, it is crucial to detect adulteration in these dietary 
      supplements. However, current methods for PDE5 inhibitor detection rely on 
      time-consuming and expensive analytical techniques, although they are sensitive. 
      In this study, we propose an aptasensor based on ellipsometry for the detection 
      of PDE5 inhibitors. To enhance the detection specificity for PDE5 inhibitors, we 
      designed an aptamer with a hydrophobic pocket that incorporates a guanine 
      base-rich region and a three-way junction. This design is particularly effective 
      considering the poor aqueous solubility of PDE5 inhibitors. Preliminary results 
      demonstrate that tadalafil detection in various media can be achieved within the 
      range of 1-2000 ng/mL. The limit of detection for the active compound of 
      tadalafil is as low as 1.82 ng/mL.
CI  - Copyright (c) 2023 Elsevier B.V. All rights reserved.
FAU - Ustundag, Ilknur
AU  - Ustundag I
AD  - Kutahya Dumlupinar University, Physics Department, Kutahya, Turkey.
FAU - Caglayan, Mustafa Oguzhan
AU  - Caglayan MO
AD  - Bilecik Seyh Edebali University, Bioengineering Department, Bilecik, Turkey. 
      Electronic address: mocaglayan@gmail.com.
LA  - eng
PT  - Journal Article
DEP - 20230713
PL  - Netherlands
TA  - Talanta
JT  - Talanta
JID - 2984816R
RN  - 742SXX0ICT (Tadalafil)
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - BW9B0ZE037 (Sildenafil Citrate)
RN  - 5O8R96XMH7 (Vardenafil Dihydrochloride)
RN  - 0 (Carbolines)
RN  - 0 (Piperazines)
RN  - 0 (Imidazoles)
RN  - 0 (Purines)
RN  - 0 (Sulfones)
SB  - IM
MH  - Male
MH  - Humans
MH  - Tadalafil
MH  - *Phosphodiesterase 5 Inhibitors
MH  - Sildenafil Citrate
MH  - Vardenafil Dihydrochloride
MH  - *Carbolines/adverse effects
MH  - Piperazines/therapeutic use
MH  - Imidazoles
MH  - Purines
MH  - Sulfones
OTO - NOTNLM
OT  - Adulteration
OT  - Aptasensors
OT  - PDE5 inhibitors
OT  - Spectrophotometric ellipsometry
COIS- Declaration of competing interest The authors declare that they have no known 
      competing financial interests or personal relationships that could have appeared 
      to influence the work reported in this paper.
EDAT- 2023/07/17 00:41
MHDA- 2023/09/20 06:42
CRDT- 2023/07/16 18:04
PHST- 2022/12/28 00:00 [received]
PHST- 2023/07/04 00:00 [revised]
PHST- 2023/07/11 00:00 [accepted]
PHST- 2023/09/20 06:42 [medline]
PHST- 2023/07/17 00:41 [pubmed]
PHST- 2023/07/16 18:04 [entrez]
AID - S0039-9140(23)00691-4 [pii]
AID - 10.1016/j.talanta.2023.124940 [doi]
PST - ppublish
SO  - Talanta. 2024 Jan 1;266(Pt 1):124940. doi: 10.1016/j.talanta.2023.124940. Epub 
      2023 Jul 13.